New therapy for Alzheimer disease

Here we present a new treatment to reduce symptoms of dementia observed in patients suffering from Alzheimer’s disease (AD).
For this patients, dementia is due to a decrease in brain cholinergic activity, leading to glutamatergic excitotoxicity that results in neuronal death, characterized clinically by a loss of learning and memory abilities.

Memantine: acts as a non-competitive low-affinity modulator of N-methyl-D-aspartate (NMDA) receptors. Memantine’s modulation of NMDA receptors has been reported to prevent the neuronal necrosis induced by glutamatergic calcium neurotoxicity

Vitamin D: this steroid hormone acts on apoptosis by protecting neuronal cells from calcium increasing.

Our technology: The researchers have developped a new drug based on the combination of these two components, therefore taking advantages of both effects.

This treatment allows partial recovery of cognitive function. This have been proved by a gain of 3 to 4 points on MMSE score. This is drastically more efficient compared to the existing treatments, todays improving the MMSE score from 0.3 to 1.5 points only